A recent study from the Department of Psychiatry and Psychotherapy, Georg-August-University Goettingen, Goettingen, Germany shows that “Reducing HDAC6 ameliorates cognitive deficits in a mouse model for Alzheimer’s disease.” This study was published in the 5 Jan’13 issue of the journal EMBO Mol Medicine.
On the foundation of this interesting finding, Dr L Boominathan PhD, Director-cum-chief Scientist of GBMD, reports that: Molecular therapy for Alzheimer’s disease: Suberoylanilide hydroxamic acid (SAHA) ameliorates cognitive deficits in Alzheimer’s disease patients via down regulation of its target gene.
Significance:
Given that (1) in 2006, 26.6 million people worldwide’re afflicted by Alzheimer’s disease; (2) the number of cases diagnosed with Alzheimer’s disease may increase from 26.6 million people in 2006 to 106.4 million in 2050 worldwide; (3) Alzheimer’s disease is the forth leading cause of death in US in the elderly; (4) Alzheimer’s disease is the third most costly disease to treat only after cancer and coronary heart disease; and (5) US$80–100 billion spent in US in caring for patients diagnosed with Alzheimer’s disease, there is an urgent need to find: (1) a cheaper alternative to the existing expensive drugs; and (2) a side-effect-free natural product-based drug.
This study suggests, for the first time, that Suberoylanilide hydroxamic acid (SAHA), by increasing the expression of its target gene, it may decrease the expression of HDAC6. Thereby, it may ameliorate cognitive deficits in Alzheimer’s disease patients. Thus, pharmacological formulations encompassing “Suberoylanilide hydroxamic acid (SAHA) or its analogues” may be used to improve cognitive deficits in Alzheimer’s disease patients.
Idea Proposed/Formulated by: Dr L Boominathan Ph.D.
Web: http://genomediscovery.org
Terms & Conditions apply http://genomediscovery.org/registration/terms-and-conditions/
To cite: Boominathan, Molecular therapy for Alzheimer’s disease: Suberoylanilide hydroxamic acid (SAHA) ameliorates cognitive deficits in Alzheimer’s disease patients via down regulation of its target gene, 4/May/2014, 13.10, Genome-2-Bio-Medicine Discovery center (GBMD), http://genomediscovery.org
Courtesy: When you cite drop us a line at info@genomediscovery.org
* Research cooperation
Undisclosed information: How Suberoylanilide hydroxamic acid (SAHA) decreases HDAC6 expression